These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 6877073)

  • 21. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient.
    Yogaratnam D; Miller MA; Smith BS
    Crit Care Nurs Clin North Am; 2005 Sep; 17(3):245-50. PubMed ID: 16115532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Galactose overload in the clinical evaluation of hepatic function; the half life of plasmatic galactose as measure of the glycidometabolic capacity of the liver].
    CHIESURA P
    Minerva Gastroenterol; 1957; 3(1):26-30. PubMed ID: 13451290
    [No Abstract]   [Full Text] [Related]  

  • 23. [The galactose breath test. Modification of the method and comparison with galactose elimination capacity and plasma disappearance of bromsulphatein (author's transl)].
    Grimm L; Bircher J; Preisig R
    Z Gastroenterol; 1980 Jan; 18(1):45-56. PubMed ID: 7385933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The quantitative liver function as measured by the galactose elimination capacity. II. Prognostic value and changes during disease in patients with cirrhosis.
    Lindskov J
    Acta Med Scand; 1982; 212(5):303-8. PubMed ID: 7180580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prescription of drugs in liver diseases].
    Held H
    Internist (Berl); 1980 Dec; 21(12):724-34. PubMed ID: 7009474
    [No Abstract]   [Full Text] [Related]  

  • 27. The galactose elimination capacity test: a study of the technique based on the analysis of 868 measurements.
    Fabbri A; Bianchi G; Motta E; Brizi M; Zoli M; Marchesini G
    Am J Gastroenterol; 1996 May; 91(5):991-6. PubMed ID: 8633594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of distribution in the metabolism of growth hormone in man.
    Srivastava MC; Owens D; Tompkins CV; Sönksen PH; Nabarro JD
    Biochem J; 1971 Dec; 125(3):64P-65P. PubMed ID: 5145877
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessment of liver function: the current situation.
    Van Thiel DH; Hassanein T
    J Okla State Med Assoc; 1995 Jan; 88(1):11-6. PubMed ID: 7897548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug therapy dosage in chronic liver diseases].
    Gugler R
    Med Welt; 1981 Jan; 32(3):87-9. PubMed ID: 7207137
    [No Abstract]   [Full Text] [Related]  

  • 31. [Blood clearance of galactose: its clinical interest].
    Tormo Calandin C; Colomer Terres J; Romar Mico A; Perez Modesto F; Cervera Montes M; Peris Aguirre L; Arnáu Silla A
    Rev Esp Enferm Apar Dig; 1980 Mar; 57(3):291-300. PubMed ID: 7375716
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug disposition in liver disease.
    Fruncillo RJ
    Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pharmacotherapy in severe liver failure].
    Hruby K; Kleinberger G
    Leber Magen Darm; 1982 Oct; 12(5):188-92. PubMed ID: 7182698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Elimination of digitoxin in liver diseases].
    Zilly W; Frank P; Richter E; Rietbrock N
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1663-6. PubMed ID: 1030073
    [No Abstract]   [Full Text] [Related]  

  • 35. [Coexistence of liver glycogenosis, Fanconi's syndrome and abnormal galactose metabolism in a 3-year-old child].
    Klinowska W; Iwańczak F; Jagodzińska M
    Pol Tyg Lek; 1980 Dec; 35(52):2065-6. PubMed ID: 6945566
    [No Abstract]   [Full Text] [Related]  

  • 36. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
    Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
    Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of enoxacin in subjects with renal or hepatic impairment.
    Novelli A; Reali EF; Amato M; Dami A; Fallani S; Periti P
    J Chemother; 1989 Jul; 1(4 Suppl):546-8. PubMed ID: 16312526
    [No Abstract]   [Full Text] [Related]  

  • 38. [Application of the enzymatic microassay of serum bile acids: value of the post-prandial test and of the clearance of cholic acid (author's transl)].
    Duhamel O; Chaintereuil J; Blanc F; de Paulet AC; Bertrand L
    Gastroenterol Clin Biol; 1981; 5(8-9):772-8. PubMed ID: 7297814
    [No Abstract]   [Full Text] [Related]  

  • 39. Elementary pharmacokinetics in clinical practice. 5: The effect of pathological condition on pharmacokinetics.
    Paxton JW
    N Z Med J; 1982 Feb; 95(702):116-8. PubMed ID: 6952117
    [No Abstract]   [Full Text] [Related]  

  • 40. [Does serum HCV-RNA-positive hepatitis C differ from serum HCV-RNA-negative hepatitis C?].
    Dällenbach A; Renner EL; Solioz M; Bianchi L; Schmid M; Reichen J
    Schweiz Med Wochenschr; 1995 Oct; 125(40):1855-63. PubMed ID: 7481644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.